Article Text

Download PDFPDF
Industry-sponsored cost-effectiveness study of TAVI
  1. Christopher Littlejohn1,
  2. Michael A Crilly2
  1. 1Public Health Directorate, NHS Grampian, Aberdeen, UK
  2. 2Population Health, Aberdeen University Medical School, Aberdeen, UK
  1. Correspondence to Mr Christopher Littlejohn, Specialty Registrar in Public Health, NHS Grampian, Summerfield House, 2 Eday Road, Aberdeen. AB15 6RE

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

To the Editor: The potential cost-effectiveness (CE) of adopting innovative procedures within a publically funded healthcare system is a recurring issue.1 Trans-catheter aortic valve insertion (TAVI) is not currently provided by the devolved National Health Service in Scotland, although a single high quality randomised controlled clinical trial (RCT) has demonstrated that TAVI is a clinically effective intervention for reducing the risk of death in older patients with severe aortic stenosis considered unfit for standard surgery.2 The recently published CE analysis of TAVI reports an incremental …

View Full Text


  • Linked article 302271.

  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.

Linked Articles

  • PostScript
    Maureen Watt Stuart Mealing James Eaton Mark Sculpher Pascale Brasseur Rachele Busca Neil Moat Nicolo Piazza Stephen Palmer